Myeloid Therapeutics Showcases Posters at ASGCT 2024 Annual Meeting

Myeloid Therapeutics, Inc., a clinical-stage company specializing in immunology, has announced several poster presentations at the 2024 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held in Baltimore, MD, and virtually. The event runs from May 7 to May 11, 2024. These presentations highlight Myeloid's advancements in in vivo immune cell engineering and RNA-based gene editing and delivery technologies.

Daniel Getts, Ph.D., CEO of Myeloid, emphasized that the data presented at ASGCT underscore the company's leadership in in vivo immune cell engineering. He highlighted the ongoing progress of MT-302, the world's first in vivo mRNA CAR drug development candidate. MT-302 is currently undergoing clinical trials and showing promise due to its inherent advantages for patient care. Getts also pointed out the transformative potential of Myeloid's CREATE platform, which could revolutionize treatments for cancer and rare diseases by enabling precise, RNA-mediated gene editing and delivery.

One notable poster titled "In vivo Programming of Immune Cells Using mRNA-LNP Chimeric Antigen Receptors" was presented on May 9, 2024. This presentation falls under the "Cancer - Targeted Gene and Cell Therapy" session. The abstract, published as number 1284, details how Myeloid has designed novel Chimeric Antigen Receptors (CARs) that can be expressed and function effectively in targeted immune cell populations. These CARs work by activating both innate and adaptive immune responses through the in vivo delivery of lipid nanoparticle (LNP)-formulated mRNA encoded CARs, demonstrating anti-tumor efficacy against various target antigens.

In preclinical studies, Myeloid has shown that these CARs are active in human cells and through systemic mRNA/LNP delivery in both mice and non-human primates. MT302, targeting TROP2+ epithelial malignancies, is currently being evaluated in a Phase 1 clinical trial (NCT05969041) to assess its safety and preliminary efficacy.

Another significant poster, presented on May 8, 2024, is titled "CRISPR-Enabled Autonomous Transposable Element (CREATE) for RNA-mediated gene editing and delivery." This presentation, part of the "Gene Targeting and Gene Correction New Technologies" session, is detailed in abstract number 719. Myeloid's CREATE platform combines Prime Editing with a DNA transposase, addressing the limitations of current gene delivery technologies. By merging CRISPR/Cas9 capabilities with human L1 retrotransposon, CREATE can insert large gene-sized payloads without the need for DNA donors or causing double-strand breaks.

Mechanistic studies have shown that CREATE is highly specific, with no observed off-target effects. This establishes the CREATE system as a programmable, RNA-based gene delivery platform that enables large-scale in vivo genome engineering, holding significant therapeutic potential.

Myeloid Therapeutics continues to innovate in the field of RNA technology to program immune cells, aiming to combat cancer and other serious diseases. The company is headquartered in Cambridge, MA.